Irigenin |
Katalog-Nr.GC38801 |
Irigenin ist eine Leitsubstanz und vermittelt seine antimetastatische Wirkung, indem es spezifisch und selektiv α9β1- und α4β1-Integrine-Bindungsstellen auf der C-C-Schleife der Extra-DomÄne A (EDA) blockiert. Irigenin zeigt krebshemmende Eigenschaften. Es sensibilisiert die TRAIL-induzierte Apoptose, indem es pro-apoptotische MolekÜle in Magenkrebszellen verstÄrkt.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 548-76-5
Sample solution is provided at 25 µL, 10mM.
Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and α4β1 integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells[1].
Irigenin specifically targets α9β1 and α4β1 integrin binding sites on Extra Domain A (EDA) comprising LEU46, PHE47, PRO48, GLU58, LEU59 and GLN60 in its C-C loop. Irigenin binds to the C-C loop of EDA, thereby blocking its interaction with integrins on the cell surface and thus abrogating subsequent Epithelial-Mesenchymal transition[1].
[1]. Amin A, et al. Irigenin, a novel lead from Western Himalayan chemiome inhibits Fibronectin-Extra Domain A induced metastasis in Lung cancer cells. Sci Rep. 2016 Nov 16;6:37151. [2]. Xu Y, et al. Irigenin sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells. Biochem Biophys Res Commun. 2018 Feb 12;496(3):998-1005.
Average Rating: 5
(Based on Reviews and 10 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *